Camilla Fuchs Andersen, ESC 2022: Empagliflozin for HFrEF, the Empire HF trial
The Empire-HF study aimed to investigate the effect of the empagliflozin on erythropoiesis in patients with heart failure with reduced ejection fraction (HFrEF). In this touchCARDIO interview, we speak with Dr Camilla Fuchs Andersen (Herlev Hospital, Herlev, Denmark) to discuss the Empire HF trial and provide an insight into potential mechanisms of empagliflozin on erythropoiesis and iron metabolism.
The abstract entitled ‘Direct effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What has been the impact of sodium-glucose co-transporter-2 (SGLT2) inhibitors on patients with heart failure? (0:15)
- What is known about the effect of SGLT2 inhibitors on haematocrit? (0:59)
- What were the aims, design and eligibility criteria of the Empire HF study? (1:43)
- What were the findings of the study? (2:36)
- What mechanisms can explain the observed increased erythropoiesis and changes in iron metabolism with empagliflozin? (3:37)
- What are the clinical implications of these findings? (5:14)
Disclosures: Camilla Fuchs Andersen has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!